Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eurofins Genomics Expands Express Oligo Service | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eurofins Genomics Expands Express Oligo Service

Express Oligo service aims to allow more customers to receive primers in a shorter turnaround time

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eurofins Genomics has expanded its Express Oligo service to allow more customers to receive primers in a shorter turnaround time. Express oligos are available in the U.S. at no additional fee.

Researchers use the oligos for a variety of routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. Often, they are custom designed for individual projects. Express synthesis, while not uncommon in the market, is associated with high fees. 

According to the company, the new service allows scientists to order as late as 5:00 p.m. Eastern time for next day delivery, with no additional fees and no decrease in quality. Before shipment, all oligos are fully verified with quality control methods. Last year, Eurofins Genomics relocated its main North American facility to be next to a major delivery hub and made other improvements to its production workflow to enhance quality and efficiency.  

“These improvements are part of our commitment to be the leader in reliability and quality for oligonucleotide synthesis,” said Martin Kunz, president of Eurofins Genomics. “In an era when budgets are getting tighter and timelines to deliver results are getting shorter, life sciences vendors and service providers must do everything they can to support customers. Eurofins wants to empower scientists and clinicians with the ability to pursue studies at their pace and within their budget, and not have to decide between speed and cost.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics